Apexigen, Inc.
Apexigen, Inc. (APGN): 6 pipeline candidates · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.3 months
D/E -6.63 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for Apexigen, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$9.4M
Quarterly Burn
$3.0M
Runway
10.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| 9mw0211 | Phase 2/Phase 3 |
| beovu | Approved |
| ocs-02 | Phase 2 |
| sotigalimab | Phase 2 |
| suvemcitug | Phase 3 |
| trk-950 | Phase 1 |
Frequently asked questions
How many drug candidates are in Apexigen, Inc.'s pipeline?
Apexigen, Inc. (APGN) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apexigen, Inc.'s lead drug candidate?
Apexigen, Inc.'s most advanced tracked candidate is 9mw0211 (Phase 2/Phase 3) for wet age-related macular degeneration.
What is Apexigen, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apexigen, Inc. has approximately 10.3 months of cash runway.
Get the full picture on Apexigen, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.